Prem Subramanian
Concepts (483)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papilledema | 17 | 2026 | 44 | 6.050 |
Why?
| | Optic Disk | 18 | 2026 | 57 | 5.370 |
Why?
| | Pseudotumor Cerebri | 12 | 2024 | 32 | 4.750 |
Why?
| | Optic Nerve Diseases | 16 | 2026 | 49 | 4.210 |
Why?
| | Intracranial Hypertension | 8 | 2023 | 42 | 3.770 |
Why?
| | Optic Neuropathy, Ischemic | 10 | 2023 | 31 | 3.700 |
Why?
| | Tomography, Optical Coherence | 20 | 2026 | 283 | 3.140 |
Why?
| | Vision Disorders | 19 | 2023 | 179 | 3.070 |
Why?
| | Visual Fields | 19 | 2022 | 120 | 3.020 |
Why?
| | Oculomotor Nerve Diseases | 6 | 2025 | 14 | 2.730 |
Why?
| | Ophthalmology | 9 | 2025 | 122 | 2.730 |
Why?
| | Visual Acuity | 19 | 2025 | 499 | 2.520 |
Why?
| | Eye Injuries | 5 | 2025 | 53 | 2.290 |
Why?
| | Optic Neuritis | 8 | 2023 | 44 | 2.200 |
Why?
| | Abducens Nerve Diseases | 5 | 2022 | 13 | 2.180 |
Why?
| | Ocular Motility Disorders | 3 | 2026 | 42 | 2.150 |
Why?
| | Hemianopsia | 6 | 2022 | 11 | 2.040 |
Why?
| | Exophthalmos | 5 | 2024 | 18 | 1.880 |
Why?
| | Retinal Ganglion Cells | 11 | 2026 | 124 | 1.870 |
Why?
| | Nerve Fibers | 10 | 2026 | 105 | 1.840 |
Why?
| | Fluorescein Angiography | 10 | 2021 | 197 | 1.840 |
Why?
| | Graves Ophthalmopathy | 5 | 2024 | 13 | 1.790 |
Why?
| | Carotid-Cavernous Sinus Fistula | 4 | 2021 | 9 | 1.680 |
Why?
| | Eye Diseases, Hereditary | 3 | 2019 | 15 | 1.550 |
Why?
| | Embolization, Therapeutic | 5 | 2021 | 246 | 1.540 |
Why?
| | Retinal Artery Occlusion | 2 | 2022 | 10 | 1.430 |
Why?
| | Diplopia | 7 | 2024 | 28 | 1.410 |
Why?
| | Meningioma | 4 | 2023 | 87 | 1.390 |
Why?
| | Eye Diseases | 5 | 2025 | 100 | 1.300 |
Why?
| | Humans | 141 | 2026 | 146342 | 1.230 |
Why?
| | Intraocular Pressure | 9 | 2022 | 344 | 1.220 |
Why?
| | Isaacs Syndrome | 2 | 2023 | 4 | 1.180 |
Why?
| | Astronauts | 4 | 2023 | 29 | 1.130 |
Why?
| | Orbit | 6 | 2023 | 67 | 1.100 |
Why?
| | Perceptual Disorders | 2 | 2019 | 24 | 1.100 |
Why?
| | Magnetic Resonance Imaging | 14 | 2025 | 3926 | 1.090 |
Why?
| | Optic Nerve | 6 | 2023 | 65 | 1.040 |
Why?
| | Retina | 5 | 2022 | 330 | 1.030 |
Why?
| | Space Flight | 4 | 2023 | 73 | 1.010 |
Why?
| | Orbital Diseases | 4 | 2013 | 37 | 0.990 |
Why?
| | Optic Disk Drusen | 4 | 2020 | 6 | 0.980 |
Why?
| | Color Vision Defects | 2 | 2017 | 8 | 0.960 |
Why?
| | Multiple Sclerosis | 3 | 2018 | 435 | 0.950 |
Why?
| | Trochlear Nerve Diseases | 3 | 2023 | 8 | 0.920 |
Why?
| | Neurology | 4 | 2021 | 107 | 0.920 |
Why?
| | Ophthalmic Artery | 3 | 2021 | 7 | 0.880 |
Why?
| | Orbital Neoplasms | 2 | 2018 | 28 | 0.870 |
Why?
| | Academies and Institutes | 2 | 2024 | 61 | 0.850 |
Why?
| | Glaucoma | 7 | 2026 | 267 | 0.830 |
Why?
| | Eye | 3 | 2021 | 112 | 0.810 |
Why?
| | Teratoma | 1 | 2025 | 121 | 0.800 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 99 | 0.790 |
Why?
| | Optic Atrophy, Hereditary, Leber | 4 | 2024 | 9 | 0.750 |
Why?
| | Visual Field Tests | 9 | 2020 | 36 | 0.750 |
Why?
| | Stroke | 3 | 2017 | 1287 | 0.740 |
Why?
| | Intracranial Aneurysm | 2 | 2022 | 105 | 0.740 |
Why?
| | Orbital Pseudotumor | 2 | 2018 | 3 | 0.740 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2018 | 91 | 0.710 |
Why?
| | Absorption, Physiological | 1 | 2021 | 5 | 0.710 |
Why?
| | Neuroimaging | 2 | 2024 | 307 | 0.710 |
Why?
| | Prostaglandins, Synthetic | 1 | 2021 | 5 | 0.710 |
Why?
| | Myofibroma | 1 | 2021 | 3 | 0.710 |
Why?
| | Embolism | 1 | 2022 | 49 | 0.700 |
Why?
| | Intracranial Pressure | 5 | 2023 | 64 | 0.700 |
Why?
| | Adie Syndrome | 1 | 2021 | 2 | 0.680 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 135 | 0.680 |
Why?
| | Cerebrospinal Fluid | 1 | 2021 | 88 | 0.680 |
Why?
| | Cerebral Small Vessel Diseases | 1 | 2021 | 6 | 0.680 |
Why?
| | Cognition Disorders | 1 | 2026 | 559 | 0.670 |
Why?
| | Meningeal Neoplasms | 3 | 2023 | 95 | 0.670 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.660 |
Why?
| | Adult | 43 | 2026 | 41087 | 0.660 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.660 |
Why?
| | Nasal Mucosa | 1 | 2021 | 112 | 0.660 |
Why?
| | Recreation | 1 | 2021 | 27 | 0.660 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.660 |
Why?
| | Disease Management | 3 | 2016 | 651 | 0.650 |
Why?
| | Hallucinations | 1 | 2020 | 33 | 0.640 |
Why?
| | Societies, Medical | 2 | 2024 | 907 | 0.630 |
Why?
| | Male | 56 | 2026 | 73396 | 0.630 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 109 | 0.620 |
Why?
| | Arteriovenous Malformations | 2 | 2011 | 34 | 0.620 |
Why?
| | Middle Aged | 43 | 2026 | 36619 | 0.610 |
Why?
| | Peripheral Nerves | 2 | 2020 | 73 | 0.610 |
Why?
| | Virtual Reality | 1 | 2021 | 83 | 0.590 |
Why?
| | Cognition | 2 | 2026 | 1292 | 0.590 |
Why?
| | Macula Lutea | 2 | 2019 | 21 | 0.590 |
Why?
| | Choroid | 1 | 2020 | 81 | 0.590 |
Why?
| | Female | 55 | 2026 | 79499 | 0.580 |
Why?
| | Retinopathy of Prematurity | 4 | 2023 | 183 | 0.580 |
Why?
| | Regional Blood Flow | 1 | 2021 | 507 | 0.570 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 78 | 0.570 |
Why?
| | Optic Nerve Neoplasms | 3 | 2023 | 12 | 0.570 |
Why?
| | Optic Chiasm | 5 | 2021 | 18 | 0.560 |
Why?
| | Vertigo | 1 | 2019 | 40 | 0.560 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 293 | 0.550 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2020 | 24 | 0.550 |
Why?
| | Sphenoid Sinus | 1 | 2017 | 7 | 0.530 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 15 | 0.530 |
Why?
| | Brain Concussion | 1 | 2026 | 660 | 0.520 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 79 | 0.510 |
Why?
| | Cranial Sinuses | 2 | 2014 | 16 | 0.500 |
Why?
| | Contrast Sensitivity | 2 | 2015 | 15 | 0.500 |
Why?
| | Giant Cell Arteritis | 4 | 2022 | 48 | 0.500 |
Why?
| | Visual Pathways | 2 | 2013 | 61 | 0.470 |
Why?
| | Young Adult | 20 | 2026 | 14330 | 0.460 |
Why?
| | Postural Balance | 1 | 2019 | 249 | 0.460 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.450 |
Why?
| | Color Vision | 1 | 2015 | 4 | 0.450 |
Why?
| | Arteriovenous Fistula | 2 | 2006 | 36 | 0.450 |
Why?
| | Aged | 25 | 2026 | 26432 | 0.450 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2021 | 55 | 0.450 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2015 | 36 | 0.440 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2786 | 0.440 |
Why?
| | Carotid Artery, Internal | 3 | 2021 | 45 | 0.440 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 55 | 0.440 |
Why?
| | Tuberculosis, Lymph Node | 1 | 2014 | 7 | 0.430 |
Why?
| | Tuberculosis, Ocular | 1 | 2014 | 8 | 0.430 |
Why?
| | Algorithms | 7 | 2026 | 1849 | 0.430 |
Why?
| | Nervous System Diseases | 3 | 2020 | 288 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 628 | 0.430 |
Why?
| | Keratoconjunctivitis | 1 | 2014 | 11 | 0.430 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 563 | 0.420 |
Why?
| | Aspergillosis | 2 | 2013 | 24 | 0.420 |
Why?
| | Recovery of Function | 2 | 2017 | 725 | 0.420 |
Why?
| | Cerebrovascular Disorders | 2 | 2013 | 103 | 0.420 |
Why?
| | Blindness | 2 | 2015 | 51 | 0.420 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2014 | 44 | 0.410 |
Why?
| | Cross-Sectional Studies | 9 | 2026 | 5899 | 0.400 |
Why?
| | Circle of Willis | 1 | 2013 | 7 | 0.400 |
Why?
| | Headache | 5 | 2021 | 150 | 0.400 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.390 |
Why?
| | Veterans | 1 | 2026 | 1650 | 0.390 |
Why?
| | Decompression, Surgical | 1 | 2014 | 115 | 0.390 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 63 | 0.380 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 71 | 0.380 |
Why?
| | Skin Neoplasms | 1 | 2020 | 806 | 0.370 |
Why?
| | Ophthalmologists | 2 | 2024 | 21 | 0.360 |
Why?
| | Cerebral Angiography | 4 | 2021 | 121 | 0.360 |
Why?
| | Ubiquinone | 2 | 2024 | 36 | 0.360 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 466 | 0.360 |
Why?
| | Lymphangioma | 1 | 2011 | 9 | 0.350 |
Why?
| | Medicare | 1 | 2018 | 920 | 0.350 |
Why?
| | Varicose Veins | 1 | 2011 | 16 | 0.350 |
Why?
| | Congresses as Topic | 2 | 2025 | 226 | 0.340 |
Why?
| | Retrospective Studies | 19 | 2023 | 17438 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2018 | 881 | 0.340 |
Why?
| | Diagnosis, Differential | 4 | 2023 | 1503 | 0.340 |
Why?
| | ROC Curve | 7 | 2021 | 617 | 0.330 |
Why?
| | Brain | 4 | 2024 | 2991 | 0.330 |
Why?
| | Aspergillus fumigatus | 1 | 2010 | 26 | 0.320 |
Why?
| | Follow-Up Studies | 8 | 2024 | 5439 | 0.320 |
Why?
| | Eye Infections, Fungal | 1 | 2010 | 20 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 992 | 0.320 |
Why?
| | Oculomotor Muscles | 2 | 2023 | 86 | 0.310 |
Why?
| | Brain Diseases | 1 | 2011 | 159 | 0.310 |
Why?
| | Military Medicine | 2 | 2008 | 148 | 0.280 |
Why?
| | Retinal Vein | 1 | 2008 | 14 | 0.280 |
Why?
| | Cerebrospinal Fluid Proteins | 1 | 2008 | 9 | 0.280 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1408 | 0.280 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1101 | 0.270 |
Why?
| | United States | 10 | 2024 | 16136 | 0.260 |
Why?
| | Strabismus | 1 | 2008 | 71 | 0.260 |
Why?
| | Iraq War, 2003-2011 | 1 | 2008 | 163 | 0.260 |
Why?
| | Corneal Edema | 1 | 2007 | 4 | 0.260 |
Why?
| | Ophthalmoplegia, Chronic Progressive External | 1 | 2007 | 3 | 0.260 |
Why?
| | Eye Pain | 2 | 2017 | 8 | 0.260 |
Why?
| | Mitochondrial Myopathies | 1 | 2007 | 10 | 0.260 |
Why?
| | Prostatectomy | 1 | 2007 | 93 | 0.260 |
Why?
| | Eye Movements | 2 | 2018 | 92 | 0.250 |
Why?
| | Astigmatism | 2 | 2006 | 17 | 0.250 |
Why?
| | Photorefractive Keratectomy | 2 | 2006 | 21 | 0.250 |
Why?
| | Decision Making | 1 | 2014 | 993 | 0.250 |
Why?
| | Septo-Optic Dysplasia | 1 | 2006 | 5 | 0.240 |
Why?
| | Temporal Arteries | 3 | 2022 | 45 | 0.240 |
Why?
| | Stents | 3 | 2016 | 554 | 0.240 |
Why?
| | Postoperative Complications | 3 | 2013 | 3034 | 0.240 |
Why?
| | Craniocerebral Trauma | 1 | 2008 | 173 | 0.230 |
Why?
| | Pandemics | 3 | 2025 | 1707 | 0.230 |
Why?
| | Cavernous Sinus | 2 | 2021 | 16 | 0.230 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 241 | 0.230 |
Why?
| | Pupil | 1 | 2025 | 21 | 0.230 |
Why?
| | Visual Cortex | 1 | 2006 | 84 | 0.230 |
Why?
| | Ophthalmoscopy | 3 | 2021 | 38 | 0.230 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 70 | 0.220 |
Why?
| | Transverse Sinuses | 2 | 2016 | 9 | 0.220 |
Why?
| | Adolescent | 13 | 2025 | 22557 | 0.220 |
Why?
| | Marijuana Smoking | 2 | 2025 | 249 | 0.220 |
Why?
| | Ocular Hypertension | 3 | 2015 | 72 | 0.220 |
Why?
| | Prospective Studies | 9 | 2019 | 8123 | 0.210 |
Why?
| | Retinal Artery | 1 | 2004 | 17 | 0.210 |
Why?
| | Sensitivity and Specificity | 6 | 2025 | 1998 | 0.210 |
Why?
| | Retinitis | 1 | 2004 | 21 | 0.210 |
Why?
| | Craniotomy | 1 | 2025 | 83 | 0.210 |
Why?
| | Peptide Hormones | 1 | 2004 | 11 | 0.210 |
Why?
| | Retinal Vasculitis | 1 | 2004 | 12 | 0.210 |
Why?
| | Aneurysm | 1 | 2004 | 37 | 0.210 |
Why?
| | Fatal Outcome | 1 | 2025 | 302 | 0.210 |
Why?
| | Eyelids | 1 | 2024 | 39 | 0.200 |
Why?
| | Parvovirinae | 1 | 2022 | 5 | 0.190 |
Why?
| | Laser Coagulation | 2 | 2019 | 80 | 0.190 |
Why?
| | Ultrasonography | 2 | 2021 | 788 | 0.190 |
Why?
| | Diphosphonates | 1 | 2003 | 68 | 0.190 |
Why?
| | Eyeglasses | 1 | 2003 | 27 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Paralysis | 1 | 2023 | 69 | 0.190 |
Why?
| | Arteries | 2 | 2021 | 261 | 0.190 |
Why?
| | Physicians | 2 | 2022 | 955 | 0.180 |
Why?
| | Radiation Injuries | 1 | 2004 | 149 | 0.180 |
Why?
| | Substance Abuse Detection | 1 | 2024 | 110 | 0.180 |
Why?
| | Telemedicine | 2 | 2023 | 966 | 0.180 |
Why?
| | Myopia | 1 | 2003 | 59 | 0.180 |
Why?
| | Eyelid Diseases | 1 | 2022 | 26 | 0.180 |
Why?
| | Compartment Syndromes | 1 | 2022 | 36 | 0.180 |
Why?
| | Artificial Intelligence | 3 | 2023 | 389 | 0.180 |
Why?
| | Fluorometry | 1 | 2021 | 19 | 0.180 |
Why?
| | Oculomotor Nerve | 1 | 2021 | 8 | 0.180 |
Why?
| | Dinoprost | 1 | 2021 | 51 | 0.170 |
Why?
| | Hallucinogens | 1 | 2024 | 112 | 0.170 |
Why?
| | Fundus Oculi | 2 | 2020 | 89 | 0.170 |
Why?
| | Administration, Intranasal | 1 | 2021 | 95 | 0.170 |
Why?
| | Blood Pressure | 1 | 2008 | 1765 | 0.170 |
Why?
| | Skull Base | 1 | 2021 | 53 | 0.170 |
Why?
| | Cornea | 1 | 2003 | 156 | 0.170 |
Why?
| | Weight Loss | 2 | 2024 | 858 | 0.170 |
Why?
| | Particulate Matter | 1 | 2024 | 328 | 0.170 |
Why?
| | Cannabis | 2 | 2025 | 521 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2024 | 217 | 0.170 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.160 |
Why?
| | Retinal Vessels | 1 | 2021 | 79 | 0.160 |
Why?
| | Child | 9 | 2025 | 22693 | 0.160 |
Why?
| | Endovascular Procedures | 2 | 2018 | 390 | 0.160 |
Why?
| | Lewy Bodies | 1 | 2020 | 10 | 0.160 |
Why?
| | Neuropsychological Tests | 1 | 2026 | 1149 | 0.160 |
Why?
| | Treatment Outcome | 9 | 2024 | 11821 | 0.160 |
Why?
| | Posture | 2 | 2019 | 182 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2003 | 272 | 0.160 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.160 |
Why?
| | Antigens, Viral | 1 | 2021 | 186 | 0.160 |
Why?
| | Vision, Ocular | 1 | 2020 | 48 | 0.160 |
Why?
| | Bariatric Surgery | 1 | 2024 | 250 | 0.160 |
Why?
| | Risk Factors | 7 | 2025 | 10921 | 0.160 |
Why?
| | Prostatic Neoplasms | 2 | 2007 | 972 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2017 | 8391 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 147 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 1036 | 0.150 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 340 | 0.150 |
Why?
| | Air Pollutants | 1 | 2024 | 406 | 0.150 |
Why?
| | Macular Degeneration | 1 | 2022 | 196 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2008 | 959 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3416 | 0.150 |
Why?
| | Chronic Disease | 1 | 2026 | 1827 | 0.150 |
Why?
| | Fovea Centralis | 1 | 2019 | 24 | 0.150 |
Why?
| | DNA, Viral | 1 | 2021 | 354 | 0.150 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 209 | 0.140 |
Why?
| | Health Surveys | 1 | 2021 | 511 | 0.140 |
Why?
| | Microvessels | 1 | 2020 | 98 | 0.140 |
Why?
| | Retinal Detachment | 1 | 2019 | 74 | 0.140 |
Why?
| | Ligation | 1 | 2018 | 88 | 0.140 |
Why?
| | Tonometry, Ocular | 3 | 2019 | 107 | 0.140 |
Why?
| | Dizziness | 1 | 2019 | 93 | 0.140 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 30 | 0.140 |
Why?
| | Forms and Records Control | 1 | 2018 | 21 | 0.130 |
Why?
| | Inflammation | 4 | 2023 | 2919 | 0.130 |
Why?
| | Healthy Volunteers | 1 | 2019 | 218 | 0.130 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 6 | 0.130 |
Why?
| | Gestational Age | 4 | 2023 | 990 | 0.130 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 342 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 2020 | 214 | 0.130 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 239 | 0.130 |
Why?
| | Infant | 6 | 2025 | 10114 | 0.130 |
Why?
| | Social Media | 1 | 2020 | 159 | 0.130 |
Why?
| | Headache Disorders | 1 | 2017 | 18 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Quality of Life | 4 | 2022 | 3200 | 0.130 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 1997 | 24 | 0.130 |
Why?
| | Capillaries | 1 | 2018 | 123 | 0.130 |
Why?
| | X Chromosome | 1 | 1997 | 66 | 0.120 |
Why?
| | Disease Progression | 3 | 2020 | 2867 | 0.120 |
Why?
| | Child, Preschool | 3 | 2025 | 11913 | 0.120 |
Why?
| | Arteritis | 1 | 2016 | 23 | 0.120 |
Why?
| | Accidents, Traffic | 1 | 2018 | 193 | 0.120 |
Why?
| | Area Under Curve | 2 | 2014 | 335 | 0.120 |
Why?
| | Prevalence | 2 | 2016 | 2861 | 0.120 |
Why?
| | Abducens Nerve | 1 | 2015 | 3 | 0.120 |
Why?
| | Constriction, Pathologic | 2 | 2014 | 240 | 0.120 |
Why?
| | Animals | 6 | 2024 | 38107 | 0.120 |
Why?
| | Autoantibodies | 1 | 2023 | 1500 | 0.110 |
Why?
| | Neuronal Plasticity | 2 | 2017 | 312 | 0.110 |
Why?
| | Activities of Daily Living | 1 | 2019 | 442 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 778 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 568 | 0.110 |
Why?
| | Lateral Sinus Thrombosis | 1 | 2015 | 1 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 493 | 0.110 |
Why?
| | Pyrazinamide | 1 | 2014 | 16 | 0.110 |
Why?
| | DNA Replication | 1 | 1997 | 248 | 0.110 |
Why?
| | Blood Sedimentation | 1 | 2014 | 38 | 0.110 |
Why?
| | Melanoma | 1 | 2021 | 765 | 0.110 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 286 | 0.110 |
Why?
| | Ethambutol | 1 | 2014 | 27 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1133 | 0.110 |
Why?
| | Health Policy | 1 | 2018 | 399 | 0.110 |
Why?
| | Rifampin | 1 | 2014 | 80 | 0.100 |
Why?
| | Isoniazid | 1 | 2014 | 71 | 0.100 |
Why?
| | Machine Learning | 1 | 2020 | 594 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2016 | 3647 | 0.100 |
Why?
| | Syndrome | 3 | 2019 | 380 | 0.100 |
Why?
| | Carbamazepine | 1 | 2013 | 24 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1591 | 0.090 |
Why?
| | Abscess | 1 | 2013 | 77 | 0.090 |
Why?
| | Incidence | 3 | 2022 | 2936 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2921 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 212 | 0.090 |
Why?
| | Dependovirus | 2 | 2023 | 78 | 0.090 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2012 | 13 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2219 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 582 | 0.090 |
Why?
| | Hemodynamics | 1 | 2016 | 1114 | 0.080 |
Why?
| | Vision, Binocular | 1 | 2011 | 47 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 2113 | 0.080 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 125 | 0.080 |
Why?
| | Penicillin G Benzathine | 1 | 2010 | 3 | 0.080 |
Why?
| | Syphilis Serodiagnosis | 1 | 2010 | 6 | 0.080 |
Why?
| | Penicillin G | 1 | 2010 | 7 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2013 | 253 | 0.080 |
Why?
| | Neonatal Screening | 2 | 2023 | 185 | 0.080 |
Why?
| | Genetic Therapy | 2 | 2023 | 303 | 0.080 |
Why?
| | Psychology | 1 | 2011 | 85 | 0.080 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6034 | 0.080 |
Why?
| | Obesity | 1 | 2004 | 3131 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1271 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.080 |
Why?
| | India | 2 | 2021 | 213 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2010 | 127 | 0.070 |
Why?
| | Infant, Newborn | 4 | 2023 | 6460 | 0.070 |
Why?
| | Military Personnel | 2 | 2008 | 726 | 0.070 |
Why?
| | Time Factors | 5 | 2020 | 7109 | 0.070 |
Why?
| | Venous Pressure | 1 | 2008 | 6 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1031 | 0.070 |
Why?
| | Antioxidants | 2 | 2024 | 544 | 0.070 |
Why?
| | Iraq | 1 | 2008 | 66 | 0.070 |
Why?
| | Afghanistan | 1 | 2008 | 96 | 0.070 |
Why?
| | Birth Weight | 2 | 2023 | 521 | 0.070 |
Why?
| | Escherichia coli | 1 | 1992 | 832 | 0.060 |
Why?
| | Cohort Studies | 2 | 2016 | 6077 | 0.060 |
Why?
| | Lasers, Excimer | 2 | 2006 | 30 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4580 | 0.060 |
Why?
| | Darkness | 1 | 2006 | 26 | 0.060 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2006 | 20 | 0.060 |
Why?
| | Functional Laterality | 1 | 2006 | 242 | 0.060 |
Why?
| | Maxillary Artery | 1 | 2005 | 2 | 0.050 |
Why?
| | Developed Countries | 1 | 2025 | 38 | 0.050 |
Why?
| | Growth Cones | 1 | 2004 | 6 | 0.050 |
Why?
| | Bucladesine | 1 | 2004 | 19 | 0.050 |
Why?
| | Angiography, Digital Subtraction | 1 | 2005 | 51 | 0.050 |
Why?
| | Retinal Hemorrhage | 1 | 2004 | 21 | 0.050 |
Why?
| | Platinum | 1 | 2005 | 48 | 0.050 |
Why?
| | Veins | 1 | 2005 | 68 | 0.050 |
Why?
| | Prognosis | 1 | 2013 | 4351 | 0.050 |
Why?
| | Body Constitution | 1 | 2004 | 51 | 0.050 |
Why?
| | Nerve Regeneration | 1 | 2004 | 57 | 0.050 |
Why?
| | Ghrelin | 1 | 2004 | 42 | 0.050 |
Why?
| | Receptor, IGF Type 1 | 1 | 2024 | 64 | 0.050 |
Why?
| | Mice | 1 | 2021 | 18297 | 0.050 |
Why?
| | Ganglia, Spinal | 1 | 2004 | 88 | 0.050 |
Why?
| | Growth Hormone | 1 | 2004 | 91 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2025 | 567 | 0.050 |
Why?
| | Stereotaxic Techniques | 1 | 2004 | 42 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2013 | 1325 | 0.050 |
Why?
| | Tubulin | 1 | 2004 | 124 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2006 | 329 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 98 | 0.050 |
Why?
| | NADH Dehydrogenase | 1 | 2023 | 20 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 350 | 0.050 |
Why?
| | Demography | 1 | 2024 | 274 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 520 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 386 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 249 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 248 | 0.050 |
Why?
| | Angiography | 1 | 2023 | 206 | 0.050 |
Why?
| | Prednisone | 1 | 2003 | 229 | 0.050 |
Why?
| | Mutation | 2 | 2024 | 4093 | 0.040 |
Why?
| | Baltimore | 2 | 2012 | 71 | 0.040 |
Why?
| | Methylprednisolone | 1 | 2022 | 58 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 212 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2024 | 346 | 0.040 |
Why?
| | Tissue Fixation | 1 | 2021 | 35 | 0.040 |
Why?
| | Global Health | 1 | 2025 | 403 | 0.040 |
Why?
| | Paraffin Embedding | 1 | 2021 | 33 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2022 | 327 | 0.040 |
Why?
| | Formaldehyde | 1 | 2021 | 66 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2023 | 426 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 105 | 0.040 |
Why?
| | Hospital Units | 1 | 2021 | 32 | 0.040 |
Why?
| | Cell Survival | 1 | 2024 | 1105 | 0.040 |
Why?
| | Safety | 1 | 2003 | 347 | 0.040 |
Why?
| | Spinal Cord Injuries | 1 | 2004 | 238 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1075 | 0.040 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 24 | 0.040 |
Why?
| | Light | 1 | 2003 | 401 | 0.040 |
Why?
| | Tertiary Prevention | 1 | 2019 | 3 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2019 | 17 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 474 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1942 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 268 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 12 | 0.040 |
Why?
| | Firearms | 1 | 2006 | 444 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2019 | 73 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 245 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 441 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 2070 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6073 | 0.030 |
Why?
| | Academic Medical Centers | 2 | 2012 | 561 | 0.030 |
Why?
| | Linear Models | 1 | 2021 | 857 | 0.030 |
Why?
| | Gravity, Altered | 1 | 2018 | 8 | 0.030 |
Why?
| | Centrifugation | 1 | 2018 | 29 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2019 | 248 | 0.030 |
Why?
| | Rotation | 1 | 2018 | 124 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 117 | 0.030 |
Why?
| | Acetazolamide | 1 | 2017 | 26 | 0.030 |
Why?
| | Primary Prevention | 1 | 2019 | 222 | 0.030 |
Why?
| | Hybrid Cells | 1 | 1997 | 47 | 0.030 |
Why?
| | Diuretics | 1 | 2017 | 66 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 983 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1997 | 137 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 545 | 0.030 |
Why?
| | Cricetinae | 1 | 1997 | 296 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 526 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 297 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 829 | 0.030 |
Why?
| | Azacitidine | 1 | 1997 | 168 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 140 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 361 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 382 | 0.030 |
Why?
| | Oxygen | 1 | 2021 | 997 | 0.030 |
Why?
| | Body Mass Index | 1 | 2004 | 2458 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1997 | 759 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 230 | 0.030 |
Why?
| | Vision Tests | 1 | 2015 | 22 | 0.030 |
Why?
| | Tinnitus | 1 | 2015 | 22 | 0.030 |
Why?
| | Infant, Premature | 1 | 2019 | 622 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1792 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 846 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 124 | 0.020 |
Why?
| | Itraconazole | 1 | 2013 | 8 | 0.020 |
Why?
| | Immunocompetence | 1 | 2013 | 46 | 0.020 |
Why?
| | Voriconazole | 1 | 2013 | 21 | 0.020 |
Why?
| | Vaccination | 1 | 2022 | 1449 | 0.020 |
Why?
| | Debridement | 1 | 2013 | 86 | 0.020 |
Why?
| | Insulin | 1 | 2004 | 2525 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2599 | 0.020 |
Why?
| | Chromatin | 1 | 1997 | 559 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2013 | 153 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 95 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1665 | 0.020 |
Why?
| | DNA Probes | 1 | 1992 | 57 | 0.020 |
Why?
| | Mutagenesis, Insertional | 1 | 1992 | 68 | 0.020 |
Why?
| | Neurosurgery | 1 | 2012 | 39 | 0.020 |
Why?
| | Triazoles | 1 | 2013 | 190 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 161 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2013 | 219 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 1992 | 410 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1992 | 508 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 330 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 1992 | 319 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 1038 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 532 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1712 | 0.020 |
Why?
| | Base Sequence | 1 | 1992 | 2123 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1992 | 2838 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 751 | 0.020 |
Why?
| | Postoperative Period | 1 | 2006 | 355 | 0.010 |
Why?
| | Tissue Transplantation | 1 | 2004 | 10 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
| | Axonal Transport | 1 | 2004 | 26 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1272 | 0.010 |
Why?
| | Visual Perception | 1 | 2006 | 184 | 0.010 |
Why?
| | Up-Regulation | 1 | 2004 | 841 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2537 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5586 | 0.010 |
Why?
|
|
Subramanian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|